

# FIGHTING THE COVID-19 PANDEMIC WITH CHEMICAL ENGINEERING INTUITION (AND ANALYSIS)

Matthew J Webber, Mark J McCready  
August 21, 2021

# “FIRST LECTURE”

- “Professor”
  - Create, Curate, Transmit, Knowledge
- Classroom etiquette
- Next 4 years:
  - Great time, you get to define who you will become!



# “CHEMICAL ENGINEERING”

- In many talks over the years I have referred to Chemical Engineering as the: “Ultimate Liberal Science Degree”
  - Fundamental subjects: Chemistry, Physics, Mathematics (more recently) Biology
  - Engineering topics: problem formulation, quantitative solution, design in light of uncertainty
  - Directly able to describe and give some quantification of:
    - Physiological processes, environmental phenomena (e.g., contaminants in the environment), consequences and limits of societal energy use

# PROCESS DESIGN 2021

Production of Para-xylene via Crystallization from Mixed Xylenes

Analysis of Valacyclovir Production

Direct Air Capture of Carbon Dioxide

H<sub>2</sub> Productions-Blue (H<sub>2</sub> production using steam reforming process and capturing the CO<sub>2</sub>)

"Gray" hydrogen production

Zevalin Production

Production of the Monoclonal Antibody Alemtuzumab

Cell-based Influenza Vaccine

Multi-stage separation of bio-naptha reformat

Production of Remicade (infiximab)

Trastuzumab Production

Insulin: Exploring the Industrial Production and High Cost of Treatment for Diabetes

Manufacturing Artificial Blood Using Hemoglobin-based Products

Green Hydrogen Production from Offshore Wind Farm

Design of a Natural Gas Plant Carbon Capture and Sequestration System with Armine Absorbents

Herceptin Production

Carbon Dioxide Capture with an Activated Carbon Adsorbent

An Analysis of Continuous Production of the Monoclonal Antibody Trastuzumab

Membrane based carbon dioxide capture from a natural gas power plant

# TOPICS TODAY

- Use of chemical engineering analysis to examine the spread of the virus and how we enabled “reopening” of various activities by staying below a minimum threat level
  - A finite “dose” of virus is needed to cause illness
    - We could adjust spacing and exposure time to allow safe execution of many different activities
- Description of the key details of the Pfizer Vaccine manufacturing process



# “COVID 19”

- It became apparent within the first few weeks of the pandemic, that no single field of expertise had the knowledge and quantitative tools to deal effectively with the spread of the virus or the resulting disease
  - Chemical Engineering could certainly make a contribution!
- As appropriate we begin including examples in our classes and using our expertise to help the University quickly put research into hibernation and then later helped develop a plan for safe reopening and resumption of many activities.

# INITIAL SPREAD OF THE VIRUS

- CBE 20255 “Introduction to Chemical Engineering” (Sophomore year)
  - Key topic: “Conservation of mass” (a.k.a. *chemical species*, or *particles in room*, includes chemical reactions)
- Observation: The rate of a chemical reaction depends on the “concentration” (e.g., moles/volume) of the chemicals.
- Speculation: Spread of the virus, which requires infected person (“B”) interacting with a susceptible person (“A”) would, by analogy, spread as the population density to the second power.

# CBE 20255: 4/7/20

Disease spread modeled as a  
"2nd order" chemical reaction:

Instead of  $A + B \rightarrow D$

The disease is:




A → UNINFECTED PEOPLE

B → INFECTED PEOPLE

DISEASE TRANSMISSION IS 2ND ORDER

$$r = \beta C_A C_B$$




$$\therefore \frac{dC_A}{dt} = -\beta C_A C_B$$

$$\frac{dC_B}{dt} = -\beta C_A C_B + 2\beta C_A C_B$$

$$\frac{dC_B}{dt} = \beta C_A C_B$$

COUNTY	POPULATION DENSITY	(POPULATION DENSITY) <sup>2</sup>	COVID 19 CASES
ST. JOE	585 P/mi <sup>2</sup>	3.4 × 10 <sup>5</sup>	44
MARSHALL	104	1.1 × 10 <sup>4</sup>	3
MARION	2369	5.6 × 10 <sup>6</sup>	964
NYC	26,400	7 × 10 <sup>8</sup>	411,000

cases COVID-19



This differs from the standard "SEIR" model since I use  
"concentration" (population density), not "number" of people




# HOW DOES SPREAD OCCUR ??

- Initially there was much talk about
  - Surfaces
  - Large droplets
- Evidence of Aerosol transmission was available by the end of March.
  - Another topic of CBE 20255: *Concentration of particles in the air*

# QUANTIFYING AEROSOL TRANSMISSION

By late March 2020, the following data were available. Blue seats were people who were infected during a 2 day period



CBE 20255  
Spring 2020  
Final Exam  
5/7/20

1. Potential for aerosol spread of SARS CoV 2 virus.

Relevant “mass balance”

$$V \frac{dC_A}{dt} = q_{AF} C_{AF} - q C_A + S - D$$

$$C_A = \frac{S}{q}$$

The concentration of virus carrying particles is proportional to the number emitted/time divided by the flow rate of fresh air into the room

# PARTICLE EMISSION

- Depending on:
  - Breathing, Speaking, Shouting, Singing
  - You emit a “distribution of sizes” of liquid particles that could carry the virus.
  - We can analyze this situation!




# SETTLING OF A SPHERICAL PARTICLE IN A GRAVITATIONAL FIELD

- CBE 30355 (Transport Phenomena I),
- 30357 (Biological Transport Phenomena)

# CBE 30357: LECTURE 10/31/19

## Navier-Stokes Equations



$$\left. \begin{aligned} \nabla \cdot \vec{v} &= 0 \\ \nabla p &= \mu \nabla^2 \vec{v} \end{aligned} \right\}$$

USE SPHERICAL COORDINATES

- CONTINUITY EQ.
- r-DIRECTION N.S. EQ.
- $\theta$ -DIRECTION N.S. EQ.

SEQUENTIALLY CONSIDER 3 PDE'S USING AN ASSUMED FORM OF SOLUTION

$$\left. \begin{aligned} v_r &\sim f(r) \cos \theta \\ v_\theta &\sim g(r) \sin \theta \end{aligned} \right\} \begin{array}{l} \text{FROM} \\ \text{B.C.'S} \end{array}$$

TABLE 3.4

(Continued)

Spherical coordinates

r direction

$$\rho \left[ \frac{\partial v_r}{\partial t} + v_r \frac{\partial v_r}{\partial r} + \frac{v_\theta}{r} \frac{\partial v_r}{\partial \theta} + \frac{v_\phi}{r \sin \theta} \frac{\partial v_r}{\partial \phi} - \frac{v_\theta^2 + v_\phi^2}{r} \right] = -\frac{\partial p}{\partial r} + \rho g_r$$

$$+ \mu \left[ \frac{1}{r^2} \frac{\partial}{\partial r} \left( r^2 \frac{\partial v_r}{\partial r} \right) + \frac{1}{r^2 \sin \theta} \frac{\partial}{\partial \theta} \left( \sin \theta \frac{\partial v_r}{\partial \theta} \right) + \frac{1}{r^2 \sin^2 \theta} \frac{\partial^2 v_r}{\partial \phi^2} - \frac{2v_r}{r^2} - \frac{2}{r^2} \frac{\partial v_\theta}{\partial \theta} - \frac{2}{r^2} v_\theta \cot \theta - \frac{2}{r^2 \sin^2 \theta} \frac{\partial v_\phi}{\partial \phi} \right] \quad (3.3.28a)$$

$\theta$  direction

$$\rho \left( \frac{\partial v_\theta}{\partial t} + v_r \frac{\partial v_\theta}{\partial r} + \frac{v_\theta}{r} \frac{\partial v_\theta}{\partial \theta} + \frac{v_\phi}{r \sin \theta} \frac{\partial v_\theta}{\partial \phi} + \frac{v_\theta v_r}{r} - \frac{v_\theta^2 \cot \theta}{r} \right) = -\frac{1}{r} \frac{\partial p}{\partial \theta} + \mu \left[ \frac{1}{r^2} \frac{\partial}{\partial r} \left( r^2 \frac{\partial v_\theta}{\partial r} \right) + \frac{1}{r^2 \sin \theta} \frac{\partial}{\partial \theta} \left( \sin \theta \frac{\partial v_\theta}{\partial \theta} \right) + \frac{1}{r^2 \sin^2 \theta} \frac{\partial^2 v_\theta}{\partial \phi^2} + \frac{2}{r^2} \frac{\partial v_r}{\partial \theta} - \frac{v_\theta}{r^2 \sin^2 \theta} - \frac{2 \cos \theta}{r^2 \sin^2 \theta} \frac{\partial v_\phi}{\partial \phi} \right] + \rho g_\theta \quad (3.3.28b)$$

$\phi$  direction

$$\rho \left( \frac{\partial v_\phi}{\partial t} + v_r \frac{\partial v_\phi}{\partial r} + \frac{v_\theta}{r} \frac{\partial v_\phi}{\partial \theta} + \frac{v_\phi}{r \sin \theta} \frac{\partial v_\phi}{\partial \phi} + \frac{v_\theta v_r}{r} + \frac{v_\theta v_\phi}{r} \cot \theta \right) = -\frac{1}{r \sin \theta} \frac{\partial p}{\partial \phi} + \mu \left[ \frac{1}{r^2} \frac{\partial}{\partial r} \left( r^2 \frac{\partial v_\phi}{\partial r} \right) + \frac{1}{r^2 \sin \theta} \frac{\partial}{\partial \theta} \left( \sin \theta \frac{\partial v_\phi}{\partial \theta} \right) + \frac{1}{r^2 \sin^2 \theta} \frac{\partial^2 v_\phi}{\partial \phi^2} + \frac{2}{r^2 \sin \theta} \frac{\partial v_r}{\partial \phi} - \frac{v_\phi}{r^2 \sin^2 \theta} + \frac{2 \cos \theta}{r^2 \sin^2 \theta} \frac{\partial v_\theta}{\partial \phi} \right] + \rho g_\phi \quad (3.3.28c)$$

WE GET: SETTLING VELOCITY



Force balance on settling particle

$$\sum F = \text{GRAVITY} + \text{BUDYANCY} + \text{DRAG}$$

$$\sum F = \rho g V - \rho_f g V - 6\pi \mu R u$$

$$= \rho g \frac{4}{3} \pi R^3 - \rho_f g \frac{4}{3} \pi R^3 - 6\pi \mu R u$$

$$6\pi \mu R u = \frac{4}{3} (\rho - \rho_f) g \pi R^3$$


$$u = \frac{2}{9} \frac{(\rho - \rho_f) g R^2}{\mu}$$

Stokes' Law



# PARTICLES EMITTED BY SPEAKING


- If the transmission is by aerosol particles that are present everywhere, even in a large room, how does distance matter?



**Figure 5.** Comparison of the number size distribution of the droplets exhaled by sneeze and speech. (Online version in colour.)




# Drop emissions from speaking



Note that this is idealized: All masks leak!



# ANOTHER RELEVANT TOPIC



CBE 30357

PARTICLE CLEARING MECHANISMS

2

T.C. Carvalho et al. / International Journal of Pharmaceutics 406 (2011) 1-10





Fig. 2. The influence of particle size on deposition;  $d$ : particle diameter;  $Stk$ : Stokes number;  $\rho_p$ : particle density;  $V$ : air velocity;  $\eta$ : air viscosity;  $R$ : airway radius;  $V_{ts}$ : terminal settling velocity;  $\rho_a$ : air density;  $g$ : gravitational acceleration;  $Df$ : diffusion coefficient;  $k$ : Boltzmann's constant;  $T$ : absolute temperature;  $d_{ae}$ : aerodynamic diameter;  $\rho_a$ : unity density.

B, mass,  $m$ , and velocity,  $v$ , according to Eq. (1) (Gonda, 2004):

TORTUOUS PATH, PARTICLES STICK TO WALL: CLEARED BY CILIA.  
LONG PATH: ONLY LAST ~5 BRANCHES ABSORB OR, COULD BREATHE BACK OUT.

WHERE DO EQUATIONS COME FROM?

SOLUTION TO NAVIER-STOKES EQUATIONS FOR FLOW PAST A SPHERE:  $Re \rightarrow 0$

# MASKS—CLASSROOM, FOOTBALL (WITH PROFESSOR LEIGHTON)

Strategies for Aerosol Mitigation in a Football Competition

David T. Leighton, Jr.

Mark J. McCready





Department of Chemical and Biomolecular Engineering

University of Notre Dame

Matthew Leiszler, MD

Health Services

University of Notre Dame



A hard "p" does not occur when counting back from 100!








# MUSICAL REHEARSAL AND PERFORMANCE

- Fog tests:




Different instruments needed  
different spacing





# THE (ORIGINAL) MUSICAL

- The musical production was written by a graduating senior who had been working on it for 3 years.
- They staged scenes to hide “fans” — e.g. when the cast is sitting around a table.
- Needed to edit out the fan noise”
- They had one problem I could not help them with:
  - A kiss!





# Chemical Engineering in Support of Vaccine R&D

*The development and scalable manufacturing of many COVID vaccines, and especially mRNA vaccines, was a Herculean effort the **likes of which was unprecedented in the biotechnology sector***



*These vaccines did not just appear out of nowhere, but were a result of decades of research by many scientists and (importantly) **Chemical Engineers***


## ACCOUNTS of chemical research

### A Combinatorial Polymer Library Approach Yields Insight into Nonviral Gene Delivery

JORDAN J. GREEN,<sup>†</sup> ROBERT LANGER,<sup>†,‡</sup> AND DANIEL G. ANDERSON<sup>‡,\*</sup>

<sup>†</sup>Department of Chemical Engineering, <sup>‡</sup>The David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139

RECEIVED ON OCTOBER 25, 2007




*This dedicated research enabled modular platforms for rapid implementation*

**EXAMPLE: Moderna had a fully formulated vaccine before the first American had died of COVID (February 6, 2020)**


# What is Actually in the Vaccine?

The “**Central Dogma**” of biology:



## **The 5 components of LNP vaccines:**

1. *mRNA (codes the protein antigen — Spike)*
2. *Ionizable lipid (proprietary)*
3. *“Helper” lipid (makes a particle)*
4. *Cholesterol (stabilizes the particle)*
5. *PEG-Lipid (keeps particles from clumping)*




See the recent TED talk by **Prof. Kathryn Whitehead** (Carnegie Mellon)



# How is the Vaccine Made?

*Massively parallel small-batch production*

***Jet Impingement Mixer:***




*Scale: Pfizer now manufacturing 100M doses per month!*



# Chemical Engineering Tools to Enable Vaccine Production


## Introduction to Chemical Engineering (Sophomore Level)



**Mass is never created or destroyed!**


$$m_1 + m_2 = m_3$$

$$X_{E,1} * m_1 = X_{E,3} * m_3$$




# Chemical Engineering Tools to Enable Vaccine Production

## Thermodynamics (Sophomore Level)



### Free Energy of LNP Self-Assembly




### Dry Ice Production

*Pfizer built their own dry ice production facility because existing suppliers couldn't match the need*


# Chemical Engineering Tools to Enable Vaccine Production

## Phase Equilibrium and Separations (Junior Level)


Fundamental equation for phase equilibria  
 $f_i^I = f_i^{II}$



**Ethanol Production**




*Lipids*  
(In ethanol)



*mRNA*  
(In buffer)

*LNPs*  
(Water + Ethanol)



*Distribution*



**Vacuum Evaporator**




*(Or Solvent Exchange?)  
(or Membranes?)*

**Product Isolation**




# Chemical Engineering Tools to Enable Vaccine Production

## Transport Phenomena (Junior Level)



Ethanol Production




Product Isolation


# Chemical Engineering Tools to Enable Vaccine Production

## Chemical Reaction Engineering (Senior Level)


### Scalable synthesis of raw materials



LNPs  
(Water + Ethanol)



Distribution



Ethanol Production



Vacuum Evaporator


(Or Solvent Exchange?)  
(or Membranes?)

Product Isolation

# Chemical Engineering Tools to Enable Vaccine Production

## Process Design (Senior Level Capstone)

*How to do this rapidly, at scale, while being economical?*





# Vaccine Production Outcomes

## ***4.7 Billion doses administered globally in ~9 months***

*A combination of mRNA, adenoviral, inactivated whole virus, etc.*

*Regardless of platform, all had production issues that only chemical engineers could solve!*

## ***A variety of other supply chain/logistics components presented problems that were solved by chemical engineering intuition***

*Continuous cold-chain distribution*

*Manufacturing of needles, glass vials, consumables*

# Key Chemical Engineering Contributors

## ***Moderna Cofounder Prof. Robert Langer (MIT)***

*Most cited engineer in history*

*1000+ patents; 1500+ publications*

*~40 successful biotechnology start-ups*



## **These Contributions Were Highly Remunerative**



# Where Do Our Graduates Work? (2020)

3M Cordova	Citi	JM Schmucker	W.R. Grace
abbvie	ClearView Healthcare	Kite Pharma	Auburn University
Accenture	Design Group	Kymanox	Caltech
Aerotek for Pfizer	Dow Chemical	Lockheed Martin	Carnegie Mellon University
Ahlstrom-Munksjö	E & J Gallo Winery	Lummus Technology	ESTEEM Program UND
Air Products and Chemicals	Edwards Lifesciences	Merck	New York Medical College
Airgas	Eli Lilly	MilliporeSigma	Stanford University
Alcami Corp	Endress + Hauser	NextEra Energy Resources	Texas A&M, Med School
Anheuser-Busch	Epic Systems	P&G	UC Irvine
Archer Daniels Midland	Exelead Biopharma	Paustenbach & Associates	UNC Pharmacoengineering
Armstrong Flooring	ExxonMobil	Pfizer	University of Chicago
Armstrong World Industry	SalesForce	Technip Energies	University of Ill. Urb-Cham
Barry-Wehmiller Design	FSI Architecture, PC	Proctor & Gamble	University of Michigan
Beghou Consulting	GE Power Nuclear	PwC	University of Texas Austin
Booz Allen Hamilton	Gen. Dyn. Electric Boat	RBC Capital Markets	University of Washington
BP	GlaxoSmithKline	Realync	
Bresco Investimentos	Hecto Group	The Kraft Heinz Company	
Carrier	Honeywell	US Navy	
Catalent Pharma Solutions	Huron	Verista	
Chevron	Ipsium Diagnostics LLC	Vista Equity Partners	